Mapracorat

Mapracorat is a glucocorticoid receptor agonist that is currently under investigation for its potential use in the treatment of inflammatory and autoimmune diseases. It was first developed by Bausch Health and is classified as a nonsteroidal anti-inflammatory drug (NSAID).

Chemistry

Mapracorat is a synthetic, nonsteroidal glucocorticoid receptor agonist. It is structurally distinct from traditional steroidal glucocorticoids, which allows it to have a unique mechanism of action.

Mechanism of Action

Mapracorat binds to the glucocorticoid receptor, a type of nuclear receptor, and activates it. This activation leads to changes in gene expression that can reduce inflammation and immune response. Unlike other glucocorticoids, mapracorat has a selective effect on the glucocorticoid receptor, which may reduce the risk of side effects associated with traditional glucocorticoid therapy.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of mapracorat. These trials have shown promising results, with mapracorat demonstrating potential as a treatment for conditions such as uveitis, dermatitis, and psoriasis. However, further research is needed to fully understand the potential benefits and risks of this drug.

Potential Uses

Mapracorat has potential uses in the treatment of a variety of inflammatory and autoimmune diseases. These include, but are not limited to, uveitis, dermatitis, psoriasis, and potentially other conditions that are currently treated with traditional glucocorticoids.

See Also

• Glucocorticoid receptor
• Nonsteroidal anti-inflammatory drug
• Bausch Health
• Uveitis
• Dermatitis
• Psoriasis

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia